# Study of HCD122 in Adults With Non-Hodgkin's or Hodgkin's Lymphoma Who Have Progressed After at Least Two Prior Therapies

> **NCT00670592** · PHASE1,PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 111 (actual)

## Conditions studied

- Non-Hodgkin's Lymphoma
- Hodgkin's Lymphoma

## Interventions

- **DRUG:** HCD122

## Key facts

- **NCT ID:** NCT00670592
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-03
- **Primary completion:** 2013-02
- **Final completion:** 2013-02
- **Target enrollment:** 111 (ACTUAL)
- **Last updated:** 2020-12-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00670592

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00670592, "Study of HCD122 in Adults With Non-Hodgkin's or Hodgkin's Lymphoma Who Have Progressed After at Least Two Prior Therapies". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00670592. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*